Buzon Maria J, Martin-Gayo Enrique, Pereyra Florencia, Ouyang Zhengyu, Sun Hong, Li Jonathan Z, Piovoso Michael, Shaw Amy, Dalmau Judith, Zangger Nadine, Martinez-Picado Javier, Zurakowski Ryan, Yu Xu G, Telenti Amalio, Walker Bruce D, Rosenberg Eric S, Lichterfeld Mathias
Infectious Disease Division, Massachusetts General Hospital, Boston, Massachusetts, USA Ragon Institute of MGH, MIT and Harvard, Boston, Massachusetts, USA.
Ragon Institute of MGH, MIT and Harvard, Boston, Massachusetts, USA.
J Virol. 2014 Sep 1;88(17):10056-65. doi: 10.1128/JVI.01046-14. Epub 2014 Jun 25.
Initiation of antiretroviral therapy during the earliest stages of HIV-1 infection may limit the seeding of a long-lasting viral reservoir, but long-term effects of early antiretroviral treatment initiation remain unknown. Here, we analyzed immunological and virological characteristics of nine patients who started antiretroviral therapy at primary HIV-1 infection and remained on suppressive treatment for >10 years; patients with similar treatment duration but initiation of suppressive therapy during chronic HIV-1 infection served as controls. We observed that independently of the timing of treatment initiation, HIV-1 DNA in CD4 T cells decayed primarily during the initial 3 to 4 years of treatment. However, in patients who started antiretroviral therapy in early infection, this decay occurred faster and was more pronounced, leading to substantially lower levels of cell-associated HIV-1 DNA after long-term treatment. Despite this smaller size, the viral CD4 T cell reservoir in persons with early treatment initiation consisted more dominantly of the long-lasting central-memory and T memory stem cells. HIV-1-specific T cell responses remained continuously detectable during antiretroviral therapy, independently of the timing of treatment initiation. Together, these data suggest that early HIV-1 treatment initiation, even when continued for >10 years, is unlikely to lead to viral eradication, but the presence of low viral reservoirs and durable HIV-1 T cell responses may make such patients good candidates for future interventional studies aiming at HIV-1 eradication and cure.
Antiretroviral therapy can effectively suppress HIV-1 replication to undetectable levels; however, HIV-1 can persist despite treatment, and viral replication rapidly rebounds when treatment is discontinued. This is mainly due to the presence of latently infected CD4 T cells, which are not susceptible to antiretroviral drugs. Starting treatment in the earliest stages of HIV-1 infection can limit the number of these latently infected cells, raising the possibility that these viral reservoirs are naturally eliminated if suppressive antiretroviral treatment is continued for extremely long periods of time. Here, we analyzed nine patients who started on antiretroviral therapy within the earliest weeks of the disease and continued treatment for more than 10 years. Our data show that early treatment accelerated the decay of infected CD4 T cells and led to very low residual levels of detectable HIV-1 after long-term therapy, levels that were otherwise detectable in patients who are able to maintain a spontaneous, drug-free control of HIV-1 replication. Thus, long-term antiretroviral treatment started during early infection cannot eliminate HIV-1, but the reduced reservoirs of HIV-1 infected cells in such patients may increase their chances to respond to clinical interventions aiming at inducing a drug-free remission of HIV-1 infection.
在HIV-1感染的最早阶段开始抗逆转录病毒治疗可能会限制持久病毒储存库的播种,但早期开始抗逆转录病毒治疗的长期影响仍不清楚。在这里,我们分析了9例在原发性HIV-1感染时开始抗逆转录病毒治疗并持续接受抑制性治疗超过10年的患者的免疫和病毒学特征;将治疗持续时间相似但在慢性HIV-1感染期间开始抑制性治疗的患者作为对照。我们观察到,无论开始治疗的时间如何,CD4 T细胞中的HIV-1 DNA主要在治疗的最初3至4年内衰减。然而,在早期感染时开始抗逆转录病毒治疗的患者中,这种衰减发生得更快且更明显,导致长期治疗后细胞相关HIV-1 DNA水平大幅降低。尽管规模较小,但早期开始治疗的患者中的病毒CD4 T细胞储存库更主要地由持久的中央记忆和T记忆干细胞组成。在抗逆转录病毒治疗期间,HIV-1特异性T细胞反应始终可检测到,与开始治疗的时间无关。总之,这些数据表明,即使早期开始HIV-1治疗并持续超过10年,也不太可能导致病毒根除,但低病毒储存库的存在和持久的HIV-1 T细胞反应可能使这些患者成为未来旨在根除和治愈HIV-1的干预性研究的良好候选者。
抗逆转录病毒治疗可以有效地将HIV-1复制抑制到无法检测的水平;然而,尽管进行了治疗,HIV-1仍可能持续存在,并且在停止治疗时病毒复制会迅速反弹。这主要是由于存在潜伏感染的CD4 T细胞,这些细胞对抗逆转录病毒药物不敏感。在HIV-1感染的最早阶段开始治疗可以限制这些潜伏感染细胞的数量,增加了如果持续进行抑制性抗逆转录病毒治疗极长时间,这些病毒储存库会自然消除的可能性。在这里,我们分析了9例在疾病最早几周内开始抗逆转录病毒治疗并持续治疗超过10年的患者。我们的数据表明,早期治疗加速了感染CD4 T细胞的衰减,并导致长期治疗后可检测到的HIV-1残留水平非常低,而在能够维持对HIV-1复制的自发、无药物控制的患者中,这些水平原本是可检测到的。因此,在早期感染期间开始的长期抗逆转录病毒治疗不能消除HIV-1,但此类患者中HIV-1感染细胞储存库的减少可能会增加他们对旨在诱导HIV-1感染无药物缓解的临床干预做出反应的机会。